5 Needs context
A 32-patient open-label clinical trial found 70% of hydroxychloroquine-treated COVID-19 patients cleared the virus by day 6 compared to 12.5% in the control group, and 100% cleared when combined with azithromycin.
"Nasopharyngeal samples were taken on day six of the treatment and it indicated that 70% of the hydroxychloroquine treated patients had cleared the virus compared to 12.5% in the group receiving standard of care. All of the patients who received both the antibiotic azithromycin and the hydroxychloroquine cleared the virus from their nasopharyngeal samples." (said at 0:12:25)
The host accurately summarizes the reported per-protocol findings of the early open-label, non-randomized trial by Gautret et al. (2020), which claimed that at day 6, 70% (14/20) of hydroxychloroquine-treated patients tested negative for SARS-CoV-2 compared to 12.5% (2/16) of controls, and 100% (6/6) receiving hydroxychloroquine plus azithromycin cleared the virus. However, critical context is required: the study suffered from severe methodological flaws, including non-randomized control selection and per-protocol exclusion of six treated patients (including three admitted to the ICU and one who died). Furthermore, the publication was formally retracted by the International Journal of Antimicrobial Agents due to ethical and methodological issues, and subsequent large-scale randomized controlled trials failed to replicate these benefits.
- context: RETRACTED: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an o… (International journal of antimicrobial agents 2020)RETRACTED · cited 4968x in the literature
"Twenty cases were treated in this study and showed a significant reduction of the viral carriage at D6-post inclusion compared to controls, and much lower average carrying duration than reported in the litterature for untreated patients. Azithromycin added to hydroxychloroquine was significantly more efficient for virus elimination." (abstract, results, passage verified)
pubmedfull study (doi) - context: Commentary on "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of … (Journal of market access & health policy 2020) · cited 18x in the literature
"The study has a number of limitations, including small sample size, lack of comparability between patients in active treatment and control arms, lack of blinding, use of interim analyses without controlling for the risk of type 1 error, use of analysis in the per-protocol population instead of the intention-to-treat population, and inconsistencies between the study protocol and article." (abstract, results, passage verified)
pubmedfull study (doi)
In vitro studies found hydroxychloroquine to be three times more potent at inhibiting SARS-CoV-2 than chloroquine phosphate.
"Hydroxychloroquine was found to be three times more potent at killing the SARS-CoV-2 virus than chloroquine phosphate in cells in culture." (said at 0:17:31)
In an early in vitro and pharmacokinetic modeling study using SARS-CoV-2-infected Vero cells (Yao et al., 2020), hydroxychloroquine demonstrated greater in vitro potency against SARS-CoV-2 than chloroquine (EC50 of 0.72 μM vs 5.47 μM, roughly a 7.6-fold difference). The specific 'three times the potency' figure originated from physiologically based pharmacokinetic (PBPK) simulations of lung fluid drug concentrations comparing a proposed hydroxychloroquine dosing regimen against chloroquine phosphate (500 mg twice daily), rather than direct cell culture assay measurements alone. In vitro and pharmacokinetic modeling data provide very low certainty evidence regarding clinical efficacy or viral clearance in humans.
The ACE2 gene is located on the X chromosome, giving women two copies and higher expression levels than men.
"The ACE2 gene is located on the X chromosome. And so, women have two X chromosomes, and so, they have more copies of the ACE2 gene and therefore higher levels." (said at 0:37:33)
The ACE2 gene is indeed located on the X chromosome (Xp22.2), meaning females carry two copies (alleles) while males carry one. However, having two copies does not automatically result in doubled or uniformly higher ACE2 expression due to X-chromosome inactivation (XCI), which silences most genes on one female X chromosome for dosage compensation. Research indicates that ACE2 can partially escape XCI in specific tissues (such as alveolar type 2 cells) and its expression is also modulated by sex hormones like estrogen, leading to higher expression in certain cell types; however, circulating and tissue-level ACE2 expression varies considerably across human tissues, and circulating soluble ACE2 levels in humans are frequently reported to be higher in males.
- context: COVID-19 and Individual Genetic Susceptibility/Receptivity: Role of ACE1/ACE2 Genes, Immun… (International journal of molecular sciences 2020) · cited 405x in the literature
"it is interesting to note that the ACE2 gene lays on the X-chromosome, thus allowing females to be potentially heterozygous and differently assorted compared to men who are definitely hemizygous. Secondly, the higher ACE2 expression rate in females, though controversial, might ascribe them the worst prognosis, in contrast with worldwide epidemiological data." (abstract, results, passage verified)
pubmedfull study (doi) - context: Gender susceptibility to COVID-19: a review of the putative role of sex hormones and X chr… (Journal of endocrinological investigation 2021) · cited 125x in the literature
"On one hand, ACE2 expression could be increased in women, either by estrogens or constitutively by X chromosome inactivation escape or by reduced methylation, providing a larger reservoir of ACE2 to maintain the fundamental equilibrium of RAS regulatory axis." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Unusual X chromosome inactivation maintenance in female alveolar type 2 cells is correlate… (Stem cell reports 2023) · cited 16x in the literature
"We demonstrate that about 68% of expressed X-linked genes in mouse AT2s, including Ace2, escape XCI." (abstract, results, passage verified)
pubmedfull study (doi)
Exposure to a 163°F sauna for 30 minutes increased heat shock protein levels by approximately 50% in healthy young men and women, with levels remaining elevated for up to 48 hours.
"Heat shock proteins have been shown to be increased by approximately 50% after 30 minutes in a 163° F sauna in healthy young men and women. Once activated, they can remain so for up to 48 hours." (said at 0:48:53)
Hyperthermic passive heat exposure, including sauna bathing, induces the cellular heat shock response and transiently increases heat shock protein (such as HSP70/HSP72) expression in human tissues and leukocytes. While narrative reviews and physiological studies confirm that heat stress triggers cytoprotective heat shock protein upregulation that can persist for 24 to 48 hours in cellular and animal models, human sauna trials show substantial variability in the magnitude of induction (dependent on baseline fitness, temperature, and tissue sampled) rather than a fixed ~50% elevation across healthy young men and women.
- partial: Effects of sauna bathing on stress-related genes expression in athletes and non-athletes. (Annals of agricultural and environmental medicine : AAEM 2017) · cited 23x in the literature
"Differences were observed in leukocyte mRNA levels of tested genes between athletes and non-athletes. In the non-athlete group, all the tested genes were expressed at higher levels as a response to the same heat challenge." (abstract, results, passage verified)
pubmedfull study (doi) - context: Sauna use as a lifestyle practice to extend healthspan. (Experimental gerontology 2021) · cited 73x in the literature
"Sauna use, sometimes referred to as "sauna bathing," is characterized by short-term passive exposure to high temperatures, typically ranging from 45 °C to 100 °C (113 °F to 212 °F), depending on modality. This exposure elicits mild hyperthermia, inducing a thermoregulatory response involving neuroendocrine, cardiovascular, and cytoprotective mechanisms that work in a synergistic fashion in an attempt to maintain homeostasis." (abstract, background and results, passage verified)
pubmedfull study (doi)
In the CITRIS-ALI trial, patients receiving intravenous vitamin C had fewer ventilator days, spent 7 days in the ICU compared to 10 days for placebo, and had hospital stays approximately one week shorter.
"Patients who received vitamin C had fewer ventilated days, spent less time in intensive care, 7 days versus 10, and their hospital stays were approximately 1 week shorter than those who received the placebo." (said at 0:58:35)
In the CITRIS-ALI randomized controlled trial (Fowler et al., 2019), intravenous vitamin C infusion did not meet its primary end points (change in SOFA organ failure scores, CRP, or thrombomodulin levels). Among exploratory secondary end points, patients in the vitamin C group did demonstrate significantly more ICU-free days to day 28 (mean difference of ~3 days, corresponding to roughly 7 vs 10 ICU days), more ventilator-free days, and more hospital-free days to day 60 (approximately 7 days / 1 week shorter hospital stay). However, because these were exploratory secondary outcomes among 43 tested end points without adjustment for multiple comparisons, the trial authors and standard evidence guidelines consider these findings hypothesis-generating rather than confirmatory.
Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.